Search clinical trials for: Alcohol pharmacokinetics

Total 15412 results

Changchun Intellicrown Pharmaceutical Co. LTD

Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Tasly Biopharmaceuticals Co., Ltd.

Recruiting

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

Nonalcoholic Steatohepatitis

United States
Alexion Pharmaceuticals, Inc.

Recruiting

Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)

Generalized Myasthenia Gravis | gMG

Spain, Italy, United States, France, Switzerland, Serbia, Japan, Netherlands
IlDong Pharmaceutical Co Ltd
Parexel; YUNOVIA CO.,LTD.

Recruiting

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

Healthy Participants

United States
Corcept Therapeutics

Recruiting

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH)

United States
Eli Lilly and Company

Recruiting

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease

United States, Japan
ParaPRO LLC
Iqvia Pty Ltd; Medpace, Inc.; Concentrics Research; Inotiv Laboratories; BioAgilytix

Recruiting

PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies

Scabies

United States
BAR Pharmaceuticals s.r.l.

Not yet recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects

Non-Alcoholic Fatty Liver Disease

Portugal
Corcept Therapeutics

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Boston Medical Center
Boston University; Eunice Kennedy Shriver National Institute of Child Health... and other collaborators

Recruiting

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

Pregnancy, High Risk | Alcohol Use Disorder | Opioid-use Disorder | Neonatal Abstinence Syndrome

United States
Boston Pharmaceuticals

Active, not recruiting

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
National Institute of Diabetes and Digestive and...

Completed

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

Obesity | Diabetes | Fatty Liver | Healthy Volunteers

United States
AstraZeneca

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.

Heathy Participants

Japan
Genentech, Inc.

Terminated

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis (BANFF)

Non-alcoholic Steatohepatitis

Belgium, United States, Spain, Puerto Rico, France
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224

Steatohepatitis, Nonalcoholic

United States, Puerto Rico
AstraZeneca

Completed

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | NASH | Fatty Liver, Nonalcoholic

United States
Sunshine Lake Pharma Co., Ltd.

Completed

A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis

Non-Alcoholic Steatohepatitis

China
Pfizer

Completed

A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT

Hepatic Impairment | Healthy Participants

Czechia, Slovakia, Belgium
AstraZeneca
Parexel

Completed

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Non-alcoholic Steatohepatitis (NASH)

United States
Ensysce Biosciences
National Institute on Drug Abuse (NIDA); Quotient Sciences

Completed

Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (MPAR-101)

Pharmacokinetics

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

Non-alcoholic Steatohepatitis

United Kingdom
Pop Test Oncology LLC
Baylor College of Medicine; Michael E. DeBakey VA Medical Center; Congressionally... and other collaborators

Completed

Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)

Potential Treatment for Alcohol Dependence-Alcohol Interaction

United States
Cascade Pharmaceuticals, Inc
Laboratory Corporation of America

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

Nonalcoholic Steatohepatitis (NASH)

United States
Madrigal Pharmaceuticals, Inc.

Completed

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Hepatic Impairment | NASH - Nonalcoholic Steatohepatitis | Cirrhosis, Liver

United States
Terns, Inc.

Completed

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
Corcept Therapeutics

Active, not recruiting

A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Anders Fink-Jensen, MD, DMSci
The Neurobiology Research Unit at Copenhagen University Hospital Rigshospitalet

Active, not recruiting

Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

Alcohol Use Disorder (AUD)

Denmark
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

United States, Belgium, France, Puerto Rico, United Kingdom
AstraZeneca

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants

Healthy Participants

Japan
Corcept Therapeutics

Completed

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH) | Antipsychotic Induced Weight Gain

United States
Delpor, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)

Opiod Use Disorder

Australia
Durect
CTI Clinical Trial and Consulting Services

Completed

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis (AH)

Alcoholic Hepatitis

United States
Zogenix, Inc.

Completed

A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)

Healthy
Terns, Inc.

Completed

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
Corcept Therapeutics

Terminated

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Terns, Inc.

Completed

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
Poxel SA

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.

NASH - Nonalcoholic Steatohepatitis

United Kingdom
Scilex Pharmaceuticals, Inc.

Completed

Pharmacokinetics of SP-104

Healthy

New Zealand
Indiana University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA) (GPRA)

Alcoholism

United States
Genfit

Terminated

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

Non Alcoholic Steatohepatitis

United States
Opiant Pharmaceuticals Inc

Completed

Pharmacokinetic Evaluation of Intranasal Nalmefene

Pharmacokinetics

United States
Enanta Pharmaceuticals, Inc
ICON Clinical Research; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

Non-Alcoholic Steatohepatitis

United States, United Kingdom, New Zealand, Canada, France, Puerto Rico
Guangdong Raynovent Biotech Co., Ltd

Completed

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics

Nonalcoholic Steatohepatitis

China
Poxel SA

Completed

A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

Nonalcoholic Fatty Liver

United States
Blade Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

NASH - Nonalcoholic Steatohepatitis | Chronic Liver Disease

Australia
Sunshine Lake Pharma Co., Ltd.

Completed

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

Australia
Pfizer

Completed

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Synchroneuron Inc.

Withdrawn

A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome

Tourette Syndrome

United States
Galecto Biotech AB

Completed

A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects

Safety and Tolerability

United Kingdom
Galecto Biotech AB
Covance

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Non-alcoholic Steatohepatitis (NASH)

3

Subscribe